Abstract
Asthma continues to be a significant health care problem, as reflected by the increasing rise in disease morbidity and mortality. Because steroids are relatively safe, clinically effective, and easy to administer, they remain the gold standard of treatment. After many decades of use, however, it is apparent that inhaled corticosteroids have failed to halt the progression of the asthma epidemic. Newer, more effective drugs are being developed to combat this disease, and the interest in developing new medications to treat allergic disease and asthma has increased exponentially. The financial burden of asthma has also been a significant motivating factor in the development of new medications. It is estimated that in 1998 the total cost of asthma on society was $11 billion [175]. This consideration has further intensified the quest to develop more effective asthma medications. Table 1 reviews the wide array of drugs currently being investigated. With the development and approval of novel asthma treatments, millions of asthma sufferers will undoubtedly have increased therapeutic options for control of their disease in the near future.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1131-1156 |
| Number of pages | 26 |
| Journal | Medical Clinics of North America |
| Volume | 86 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 2002 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Asthma : Future directions. / Leonard, Patricia; Sur, Sanjiv.
In: Medical Clinics of North America, Vol. 86, No. 5, 09.2002, p. 1131-1156.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Asthma
T2 - Future directions
AU - Leonard, Patricia
AU - Sur, Sanjiv
PY - 2002/9
Y1 - 2002/9
N2 - Asthma continues to be a significant health care problem, as reflected by the increasing rise in disease morbidity and mortality. Because steroids are relatively safe, clinically effective, and easy to administer, they remain the gold standard of treatment. After many decades of use, however, it is apparent that inhaled corticosteroids have failed to halt the progression of the asthma epidemic. Newer, more effective drugs are being developed to combat this disease, and the interest in developing new medications to treat allergic disease and asthma has increased exponentially. The financial burden of asthma has also been a significant motivating factor in the development of new medications. It is estimated that in 1998 the total cost of asthma on society was $11 billion [175]. This consideration has further intensified the quest to develop more effective asthma medications. Table 1 reviews the wide array of drugs currently being investigated. With the development and approval of novel asthma treatments, millions of asthma sufferers will undoubtedly have increased therapeutic options for control of their disease in the near future.
AB - Asthma continues to be a significant health care problem, as reflected by the increasing rise in disease morbidity and mortality. Because steroids are relatively safe, clinically effective, and easy to administer, they remain the gold standard of treatment. After many decades of use, however, it is apparent that inhaled corticosteroids have failed to halt the progression of the asthma epidemic. Newer, more effective drugs are being developed to combat this disease, and the interest in developing new medications to treat allergic disease and asthma has increased exponentially. The financial burden of asthma has also been a significant motivating factor in the development of new medications. It is estimated that in 1998 the total cost of asthma on society was $11 billion [175]. This consideration has further intensified the quest to develop more effective asthma medications. Table 1 reviews the wide array of drugs currently being investigated. With the development and approval of novel asthma treatments, millions of asthma sufferers will undoubtedly have increased therapeutic options for control of their disease in the near future.
UR - http://www.scopus.com/inward/record.url?scp=0036710089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036710089&partnerID=8YFLogxK
U2 - 10.1016/S0025-7125(02)00037-8
DO - 10.1016/S0025-7125(02)00037-8
M3 - Article
VL - 86
SP - 1131
EP - 1156
JO - Medical Clinics of North America
JF - Medical Clinics of North America
SN - 0025-7125
IS - 5
ER -